TapewireFind a company

person · Reporting owner

Mahal Jeetinder Singh

Disclosed activity across 1 company

Tapewire entity
67062
SEC CIK
0001882877

Export transaction history ↓

Reported relationships

Latest disclosed role at each company.

CompanyLast reported asReport datePublished
Jasper Therapeutics, Inc.JSPR · Entity 7588Director · CEO and PresidentFebruary 06, 2026February 10, 2026

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

Jasper Therapeutics, Inc.

Report date February 06, 2026 · Filed February 10, 2026

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.35 · Expires 2036-02-06Direct500,000 Reported balance After 2026-02-06 transaction · row 1 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 1 · 2026-02-06 · Grant · Acquired 500,000 · Balance 500,000

F1: 1/4th of the shares subject to the option shall vest on February 6, 2027, and 1/48th of the original number of shares subject to the option shall vest following each one-month period thereafter, subject to the Reporting Person's continuous service to the Issuer on and through each applicable vesting date, inclusive.

Filing footnotes · ownership attribution and instrument terms

F1: 1/4th of the shares subject to the option shall vest on February 6, 2027, and 1/48th of the original number of shares subject to the option shall vest following each one-month period thereafter, subject to the Reporting Person's continuous service to the Issuer on and through each applicable vesting date, inclusive.

Transaction history

JSON API
Reset

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction dateCompanyActivity / securityShares / unitsReported priceReported valueDetails
February 06, 2026 Filed Feb 10, 2026 16:00 UTC Jasper Therapeutics, Inc. JSPR · Entity 7588 GrantStock Option (right to buy) · Derivative 500,000 $0.00 Strike: $1.35 $0.00
Disclosure

SEC source: 0001213900-26-014244 · ownership.xml · derivative · entry 1

Mahal Jeetinder Singh · CIK 0001882877 · Director · CEO and President

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 500,000

Underlying: Voting Common Stock · 500,000 shares

Expires 2036-02-06

F1 · derivative.exercise_date: 1/4th of the shares subject to the option shall vest on February 6, 2027, and 1/48th of the original number of shares subject to the option shall vest following each one-month period thereafter, subject to the Reporting Person's continuous service to the Issuer on and through each applicable vesting date, inclusive.

Read SEC document
January 02, 2026 Filed Jan 5, 2026 19:30 UTC Jasper Therapeutics, Inc. JSPR · Entity 7588 GrantStock Option (right to buy) · Derivative 90,000 $0.00 Strike: $1.84 $0.00
Disclosure

SEC source: 0001213900-26-001383 · ownership.xml · derivative · entry 1

Mahal Jeetinder Singh · CIK 0001882877 · Chief Operating Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 90,000

Underlying: Voting Common Stock · 90,000 shares

Expires 2036-01-02

F1 · derivative.exercise_date: 1/4th of the shares subject to the option shall vest on January 2, 2027, and 1/48th of the original number of shares subject to the option shall vest following each one-month period thereafter, subject to the Reporting Person's continuous service to the Issuer on and through each applicable vesting date, inclusive.

Read SEC document
June 04, 2025 Filed Jun 6, 2025 06:27 UTC Jasper Therapeutics, Inc. JSPR · Entity 7588 GrantStock Option (right to buy) · Derivative 90,000 $0.00 Strike: $6.00 $0.00
Disclosure

SEC source: 0001213900-25-051726 · ownership.xml · derivative · entry 1

Mahal Jeetinder Singh · CIK 0001882877 · Chief Operating Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 90,000

Underlying: Voting Common Stock · 90,000 shares

Expires 2035-06-04

F1 · derivative.exercise_date: 1/4th of the shares subject to the retention option shall vest on June 4, 2026 and 1/48th of the shares subject to the retention option shall vest following each one-month period thereafter, subject to the Reporting Person's continuous service to the Issuer on and through each applicable vesting date, inclusive.

Read SEC document
February 13, 2025 Filed Feb 18, 2025 17:31 UTC Jasper Therapeutics, Inc. JSPR · Entity 7588 GrantStock Option (right to buy) · Derivative 50,000 $0.00 Strike: $6.20 $0.00
Disclosure

SEC source: 0001213900-25-014951 · ownership.xml · derivative · entry 1

Mahal Jeetinder Singh · CIK 0001882877 · Chief Operating Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 50,000

Underlying: Voting Common Stock · 50,000 shares

Expires 2035-02-13

F1 · derivative.exercise_date: 1/4th of the shares subject to the option shall vest on February 13, 2026, and 1/48th of the original number of shares subject to the option shall vest following each one-month period thereafter, subject to the Reporting Person's continuous service to the Issuer on and through each applicable vesting date, inclusive.

Read SEC document
December 12, 2024 Filed Dec 12, 2024 20:02 UTC Jasper Therapeutics, Inc. JSPR · Entity 7588 Exercise / conversionStock Option (right to buy) · Derivative 900 $0.00 Strike: $7.10 $0.00
Disclosure

SEC source: 0001213900-24-108551 · ownership.xml · derivative · entry 3

Mahal Jeetinder Singh · CIK 0001882877 · Chief Operating Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 13,772

Underlying: Voting Common Stock · 900 shares

Expires 2030-05-31

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 15, 2023.

F2 · derivative.exercise_date: 25% of the original number of shares subject to the option vested on December 12, 2020, and 1/48th of the original number of shares subject to the option vested monthly thereafter.

Read SEC document
December 12, 2024 Filed Dec 12, 2024 20:02 UTC Jasper Therapeutics, Inc. JSPR · Entity 7588 SaleVoting Common Stock 900 $22.11 $19,899.00
Disclosure

SEC source: 0001213900-24-108551 · ownership.xml · nonDerivative · entry 2

Mahal Jeetinder Singh · CIK 0001882877 · Chief Operating Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 25,009

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 15, 2023.

Read SEC document
December 12, 2024 Filed Dec 12, 2024 20:02 UTC Jasper Therapeutics, Inc. JSPR · Entity 7588 Exercise / conversionVoting Common Stock 900 $7.10 $6,390.00
Disclosure

SEC source: 0001213900-24-108551 · ownership.xml · nonDerivative · entry 1

Mahal Jeetinder Singh · CIK 0001882877 · Chief Operating Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 25,909

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 15, 2023.

Read SEC document
September 12, 2024 Filed Sep 12, 2024 17:19 UTC Jasper Therapeutics, Inc. JSPR · Entity 7588 Exercise / conversionStock Option (right to buy) · Derivative 900 $0.00 Strike: $7.10 $0.00
Disclosure

SEC source: 0001213900-24-078214 · ownership.xml · derivative · entry 3

Mahal Jeetinder Singh · CIK 0001882877 · Chief Operating Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 14,672

Underlying: Voting Common Stock · 900 shares

Expires 2030-05-31

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 15, 2023.

F3 · derivative.exercise_date: 25% of the original number of shares subject to the option vested on December 12, 2020, and 1/48th of the original number of shares subject to the option vested monthly thereafter.

Read SEC document
September 12, 2024 Filed Sep 12, 2024 17:19 UTC Jasper Therapeutics, Inc. JSPR · Entity 7588 SaleVoting Common Stock 900 $21.23 $19,103.67
Disclosure

SEC source: 0001213900-24-078214 · ownership.xml · nonDerivative · entry 2

Mahal Jeetinder Singh · CIK 0001882877 · Chief Operating Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 25,009

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 15, 2023.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $20.795 to $21.495, inclusive. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer full information regarding the number of shares purchased or sold at each separate price.

Read SEC document
September 12, 2024 Filed Sep 12, 2024 17:19 UTC Jasper Therapeutics, Inc. JSPR · Entity 7588 Exercise / conversionVoting Common Stock 900 $7.10 $6,390.00
Disclosure

SEC source: 0001213900-24-078214 · ownership.xml · nonDerivative · entry 1

Mahal Jeetinder Singh · CIK 0001882877 · Chief Operating Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 25,909

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 15, 2023.

Read SEC document
June 12, 2024 Filed Jun 12, 2024 21:40 UTC Jasper Therapeutics, Inc. JSPR · Entity 7588 Exercise / conversionStock Option (right to buy) · Derivative 900 $0.00 Strike: $7.10 $0.00
Disclosure

SEC source: 0001213900-24-052215 · ownership.xml · derivative · entry 3

Mahal Jeetinder Singh · CIK 0001882877 · Chief Operating Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 15,572

Underlying: Voting Common Stock · 900 shares

Expires 2030-05-31

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 15, 2023.

F3 · derivative.exercise_date: 25% of the original number of shares subject to the option vested on December 12, 2020, and 1/48th of the original number of shares subject to the option vested monthly thereafter.

Read SEC document
June 12, 2024 Filed Jun 12, 2024 21:40 UTC Jasper Therapeutics, Inc. JSPR · Entity 7588 SaleVoting Common Stock 900 $24.16 $21,739.50
Disclosure

SEC source: 0001213900-24-052215 · ownership.xml · nonDerivative · entry 2

Mahal Jeetinder Singh · CIK 0001882877 · Chief Operating Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 25,009

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 15, 2023.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $23.975 to $24.555, inclusive. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer full information regarding the number of shares purchased or sold at each separate price.

Read SEC document
June 12, 2024 Filed Jun 12, 2024 21:40 UTC Jasper Therapeutics, Inc. JSPR · Entity 7588 Exercise / conversionVoting Common Stock 900 $7.10 $6,390.00
Disclosure

SEC source: 0001213900-24-052215 · ownership.xml · nonDerivative · entry 1

Mahal Jeetinder Singh · CIK 0001882877 · Chief Operating Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 25,909

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 15, 2023.

Read SEC document
March 12, 2024 Filed Mar 12, 2024 21:33 UTC Jasper Therapeutics, Inc. JSPR · Entity 7588 Exercise / conversionStock Option (right to buy) · Derivative 900 $0.00 Strike: $7.10 $0.00
Disclosure

SEC source: 0001213900-24-021961 · ownership.xml · derivative · entry 3

Mahal Jeetinder Singh · CIK 0001882877 · Chief Operating Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 16,472

Underlying: Voting Common Stock · 900 shares

Expires 2030-05-31

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F4 · derivative.exercise_price: The exercise price of the option and number of shares subject to the option were adjusted as a result of the Reverse Split, and numbers reported herein reflect the exercise price and number of shares subject to the option after the Reverse Split.

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 15, 2023.

F5 · derivative.exercise_date: 25% of the original number of shares subject to the option vested on December 12, 2020, and 1/48th of the original number of shares subject to the option vested monthly thereafter.

F4 · balance_after: The exercise price of the option and number of shares subject to the option were adjusted as a result of the Reverse Split, and numbers reported herein reflect the exercise price and number of shares subject to the option after the Reverse Split.

Read SEC document
March 12, 2024 Filed Mar 12, 2024 21:33 UTC Jasper Therapeutics, Inc. JSPR · Entity 7588 SaleVoting Common Stock 900 $26.44 $23,792.22
Disclosure

SEC source: 0001213900-24-021961 · ownership.xml · nonDerivative · entry 2

Mahal Jeetinder Singh · CIK 0001882877 · Chief Operating Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 25,009

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 15, 2023.

F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $26.14 to $26.79, inclusive. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer full information regarding the number of shares purchased or sold at each separate price.

Read SEC document
March 12, 2024 Filed Mar 12, 2024 21:33 UTC Jasper Therapeutics, Inc. JSPR · Entity 7588 Exercise / conversionVoting Common Stock 900 $7.10 $6,390.00
Disclosure

SEC source: 0001213900-24-021961 · ownership.xml · nonDerivative · entry 1

Mahal Jeetinder Singh · CIK 0001882877 · Chief Operating Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 25,909

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 15, 2023.

F2 · balance_after: Effective on January 4, 2024, the Issuer conducted a reverse stock split of its voting common stock at a ratio of 1-for-10 (the "Reverse Split"). The number of shares reported herein reflects the number of shares after the Reverse Split.

Read SEC document
February 15, 2024 Filed Feb 20, 2024 19:31 UTC Jasper Therapeutics, Inc. JSPR · Entity 7588 GrantStock Option (right to buy) · Derivative 40,000 $0.00 Strike: $17.95 $0.00
Disclosure

SEC source: 0001213900-24-015462 · ownership.xml · derivative · entry 1

Mahal Jeetinder Singh · CIK 0001882877 · Chief Operating Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 40,000

Underlying: Voting Common Stock · 40,000 shares

Expires 2034-02-15

F1 · derivative.exercise_date: 1/4th of the shares subject to the option shall vest on February 15, 2025, and 1/48th of the shares subject to the option shall vest following each one-month period thereafter, subject to the Reporting Person's continuous service to the Issuer on and through each applicable vesting date, inclusive.

Read SEC document
October 12, 2023 Filed Oct 13, 2023 18:58 UTC Jasper Therapeutics, Inc. JSPR · Entity 7588 Tax withholdingVoting Common Stock 37,126 $0.85 $31,557.10
Disclosure

SEC source: 0001013762-23-003903 · ownership.xml · nonDerivative · entry 1

Mahal Jeetinder Singh · CIK 0001882877 · Chief Operating Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 250,097

F1 · shares: These shares were withheld by the Issuer in order to satisfy certain tax withholding obligations in connection with the issuance of shares of the Issuer's common stock upon the vesting of restricted stock units.

Read SEC document
June 13, 2023 Filed Jun 13, 2023 20:54 UTC Jasper Therapeutics, Inc. JSPR · Entity 7588 Exercise / conversionStock Option (right to buy) · Derivative 9,000 $0.00 Strike: $0.71 $0.00
Disclosure

SEC source: 0001213900-23-048683 · ownership.xml · derivative · entry 3

Mahal Jeetinder Singh · CIK 0001882877 · See Remarks

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 173,713

Underlying: Voting Common Stock · 9,000 shares

Expires 2030-05-31

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 15, 2023.

F3 · derivative.exercise_date: 25% of the original number of shares subject to the option vested on December 12, 2020, and 1/48th of the original number of shares have vested and shall vest monthly thereafter, subject to the Reporting Person's continued service to the Issuer through each such vesting date.

Read SEC document
June 13, 2023 Filed Jun 13, 2023 20:54 UTC Jasper Therapeutics, Inc. JSPR · Entity 7588 SaleVoting Common Stock 9,000 $1.66 $14,914.80
Disclosure

SEC source: 0001213900-23-048683 · ownership.xml · nonDerivative · entry 2

Mahal Jeetinder Singh · CIK 0001882877 · See Remarks

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 287,223

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 15, 2023.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.62 to $1.69, inclusive. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer full information regarding the number of shares purchased or sold at each separate price.

Read SEC document
June 13, 2023 Filed Jun 13, 2023 20:54 UTC Jasper Therapeutics, Inc. JSPR · Entity 7588 Exercise / conversionVoting Common Stock 9,000 $0.71 $6,390.00
Disclosure

SEC source: 0001213900-23-048683 · ownership.xml · nonDerivative · entry 1

Mahal Jeetinder Singh · CIK 0001882877 · See Remarks

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 296,223

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 15, 2023.

Read SEC document
April 12, 2023 Filed Apr 14, 2023 16:16 UTC Jasper Therapeutics, Inc. JSPR · Entity 7588 Tax withholdingVoting Common Stock 37,126 $1.46 $54,203.96
Disclosure

SEC source: 0001213900-23-029893 · ownership.xml · nonDerivative · entry 1

Mahal Jeetinder Singh · CIK 0001882877 · See Remarks

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 287,223

F1 · shares: These shares were withheld by the Issuer in order to satisfy certain tax withholding obligations in connection with the issuance of shares of the Issuer's common stock upon the vesting of restricted stock units.

Read SEC document
March 17, 2023 Filed Mar 20, 2023 18:00 UTC Jasper Therapeutics, Inc. JSPR · Entity 7588 GrantStock Option (right to buy) · Derivative 350,000 $0.00 Strike: $1.87 $0.00
Disclosure

SEC source: 0001213900-23-021494 · marketforms-60959.xml · derivative · entry 1

Mahal Jeetinder Singh · CIK 0001882877 · See Remarks

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 350,000

Underlying: Voting Common Stock · 350,000 shares

Expires 2033-03-17

F1 · derivative.exercise_date: 1/4th of the shares subject to the option shall vest on March 3, 2024, and 1/48th of the shares subject to the option shall vest following each one-month period thereafter, subject to the Reporting Person's continuous service to the Issuer on and through each applicable vesting date, inclusive.

Read SEC document
October 12, 2022 Filed Oct 13, 2022 20:02 UTC Jasper Therapeutics, Inc. JSPR · Entity 7588 GrantVoting Common Stock 214,722 $0.00 $0.00
Disclosure

SEC source: 0001213900-22-063941 · ownership.xml · nonDerivative · entry 1

Mahal Jeetinder Singh · CIK 0001882877 · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 324,349

F1 · shares: The reported securities are represented by restricted stock units, 1/2 of which shall vest on each of April 12, 2023 and October 12, 2023, subject to the Reporting Person's continuous service to the Issuer on and through each applicable vesting date, inclusive.

Read SEC document
April 07, 2022 Filed Apr 8, 2022 16:01 UTC Jasper Therapeutics, Inc. JSPR · Entity 7588 GrantStock Option (right to buy) · Derivative 48,441 $0.00 Strike: $3.12 $0.00
Disclosure

SEC source: 0001213900-22-018928 · ownership.xml · derivative · entry 1

Mahal Jeetinder Singh · CIK 0001882877 · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 48,441

Underlying: Voting Common Stock · 48,441 shares

Expires 2032-04-07

F1 · derivative.exercise_date: 1/4th of the shares subject to the option shall vest on March 21, 2023, and 1/48th of the shares subject to the option shall vest following each one-month period thereafter, subject to the Reporting Person's continuous service to the Issuer on and through each applicable vesting date, inclusive.

Read SEC document
March 21, 2022 Filed Mar 23, 2022 18:02 UTC Jasper Therapeutics, Inc. JSPR · Entity 7588 GrantStock Option (right to buy) · Derivative 87,272 $0.00 Strike: $3.54 $0.00
Disclosure

SEC source: 0001213900-22-014565 · ownership.xml · derivative · entry 2

Mahal Jeetinder Singh · CIK 0001882877 · COO,CFO and CS

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 87,272

Underlying: Voting Common Stock · 87,272 shares

Expires 2032-03-21

F2 · derivative.exercise_date: 1/4th of the shares subject to the option shall vest on March 21, 2023, and 1/48th of the shares subject to the option shall vest following each one-month period thereafter, subject to the Reporting Person's continuous service to the Issuer on and through each applicable vesting date, inclusive.

Read SEC document
March 21, 2022 Filed Mar 23, 2022 18:02 UTC Jasper Therapeutics, Inc. JSPR · Entity 7588 GrantStock Option (right to buy) · Derivative 7,500 $0.00 Strike: $3.54 $0.00
Disclosure

SEC source: 0001213900-22-014565 · ownership.xml · derivative · entry 1

Mahal Jeetinder Singh · CIK 0001882877 · COO,CFO and CS

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 7,500

Underlying: Voting Common Stock · 7,500 shares

Expires 2032-03-21

F1 · derivative.exercise_date: 1/4th of the shares subject to the option shall vest on December 7, 2022, and 1/48th of the shares subject to the option shall vest following each one-month period thereafter, subject to the Reporting Person's continuous service to the Issuer on and through each applicable vesting date, inclusive.

Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.